Clipping of news on Brazilian Culture, Law and Citizenship
 


Health

Senate committee drops veto appetite suppressants

07/17/2014

This article was translated by an automatic translation system, and was therefore not reviewed by people.

 




transparent image



Committee on Constitution and Justice and Citizenship approved a proposal that releases the production and sale, prescription, drugs of the amphetamine derivatives

Marcela Mattos, Brasilia

Pills medicine
Approved remedies include amfepramone femproporex and mazindol (RF Creatas / Getty Images)

The Committee on Constitution and Justice and Citizenship (CCJ) Senate on Wednesday approved the proposal to release the production and sale, prescription of appetite suppressants amphetamine derivatives. These drugs, which include amfepramone femproporex and mazindol, were withdrawn from the market in October 2011 as determined by the National Health Surveillance Agency (ANVISA). With the decision of the board also drop restrictions on sale of sibutramine, another appetite suppressant, as dosages above 15mg/day and the need for a waiver signed by patient and physician. The text has been approved by the House of Representatives and now awaits full Senate vote.

The report adopted by the collegiate, authored by Senator Lucia Vania (PSDB-GO), points out that after the rule went into effect the obesity problem has intensified in Brazil. "According to Vigitel survey conducted by the Ministry of Health, 48% of the population was overweight in 2011. The following year, the situation has worsened, and the survey found that 51% of Brazilians were overweight," says the opinion. "Moreover, one should not ignore the marketing ban of substances led to the creation of an illegal drug market that surely will cause damage to the health of the population," he continues.

The text also says that with the ban the main substances linked to satiety, are left few options for treating the disease. "For pharmacological treatment, there were only orlistat and sibutramine. Note that orlistat has a high market price, which prevents their acquisition by the most needy patients. In the case of sibutramine, ANVISA began requiring the physician completing a disclaimer in the act of prescribing. for severe cases of obesity, remains, finally, only the extreme measure of treatment through bariatric surgery, "said the rapporteur.

The prohibition of appetite suppressants generated a clash between ANVISA and medical societies linked to obesity. The United Nations (UN) even issued report which advocated the release of these drugs for medical purposes. The prosecution of Goiás and the Federal Medical Council appealed against the resolution. Nevertheless, the measure was approved by the agency.

By fifteen votes to six, the proposal was approved on Wednesday with no changes to the text sent by the House in April. MPs allied to the Plateau, as the principal chiefs of the PT in the Senate, Humberto Costa (PE) and Gleisi Hoffmann (PR), were opposed to the release of inhibitors.


Source: See - Online

Our news are taken in full from our partner sites. For this reason, we can not change their content even in cases of typos.

This article was translated by an automatic translation system, and was therefore not reviewed by people.

Important:
The JurisWay site does not interfere in the work provided by doctrine, why only reflect the opinions, ideas and concepts of their authors.


  Subjects list
 
  Copyright (c) 2006-2009. JurisWay - All rights reserved.